Insights

Innovation in Therapeutics MoonLake Immunotherapeutics is advancing cutting-edge Nanobody technology targeting inflammatory diseases, indicating a strong focus on innovative biopharmaceutical solutions. Partnering or providing supplementary technological tools could support their R&D efforts and accelerate product development.

Growing Market Presence Having evolved from a startup to a valued billion-dollar company with recent funding of 75 million dollars, MoonLake presents a compelling opportunity for collaborations in clinical research, regulatory services, and commercialization support within the biotech industry.

Regulatory and Legal Landscape Recent securities fraud lawsuits and investigations highlight potential compliance and governance challenges. Offering legal advisory, compliance solutions, or risk management services could help mitigate issues and establish trust with their executive team.

Clinical Program Expansion With their IZAR patient screening program gaining traction, MoonLake is actively expanding its clinical pipeline. Supporting clinical trial management, patient recruitment tools, or data analytics solutions could enhance their operational efficiency.

Technology Ecosystem Needs Utilizing a broad spectrum of tech tools such as SAP, Adobe Suite, and cloud services, MoonLake may require advanced IT infrastructure, cybersecurity, and data integration services to optimize their research and operational activities.

MoonLake Immunotherapeutics (NASDAQ: MLTX) Tech Stack

MoonLake Immunotherapeutics (NASDAQ: MLTX) uses 8 technology products and services including SAP, Apple iCloud Mail, .NET, and more. Explore MoonLake Immunotherapeutics (NASDAQ: MLTX)'s tech stack below.

  • SAP
    Customer Relationship Management
  • Apple iCloud Mail
    Email
  • .NET
    Programming Languages
  • Akamai Web Application Protector
    Security
  • Adobe Tag Manager
    Tag Management
  • Adobe Creative Suite
    Visualisation Software
  • X-Content-Type-Options
    Web & Portal Technology
  • GoDaddy
    Web Hosting

Media & News

MoonLake Immunotherapeutics (NASDAQ: MLTX)'s Email Address Formats

MoonLake Immunotherapeutics (NASDAQ: MLTX) uses at least 1 format(s):
MoonLake Immunotherapeutics (NASDAQ: MLTX) Email FormatsExamplePercentage
F.Last@moonlaketx.comJ.Doe@moonlaketx.com
49%
First.Last@moonlaketx.comJohn.Doe@moonlaketx.com
1%
F.Last@moonlaketx.comJ.Doe@moonlaketx.com
49%
First.Last@moonlaketx.comJohn.Doe@moonlaketx.com
1%

Frequently Asked Questions

Where is MoonLake Immunotherapeutics (NASDAQ: MLTX)'s headquarters located?

Minus sign iconPlus sign icon
MoonLake Immunotherapeutics (NASDAQ: MLTX)'s main headquarters is located at 29 Dorfstrasse Zug, Zug 6300 Switzerland. The company has employees across 3 continents, including EuropeNorth AmericaSouth America.

What is MoonLake Immunotherapeutics (NASDAQ: MLTX)'s official website and social media links?

Minus sign iconPlus sign icon
MoonLake Immunotherapeutics (NASDAQ: MLTX)'s official website is moonlaketx.com and has social profiles on LinkedInCrunchbase.

What is MoonLake Immunotherapeutics (NASDAQ: MLTX)'s SIC code NAICS code?

Minus sign iconPlus sign icon
MoonLake Immunotherapeutics (NASDAQ: MLTX)'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does MoonLake Immunotherapeutics (NASDAQ: MLTX) have currently?

Minus sign iconPlus sign icon
As of February 2026, MoonLake Immunotherapeutics (NASDAQ: MLTX) has approximately 136 employees across 3 continents, including EuropeNorth AmericaSouth America. Key team members include Chief Financial Officer: M. B.Chief Technical Officer: O. D.Chief Medical Officer: W. O. B.. Explore MoonLake Immunotherapeutics (NASDAQ: MLTX)'s employee directory with LeadIQ.

What industry does MoonLake Immunotherapeutics (NASDAQ: MLTX) belong to?

Minus sign iconPlus sign icon
MoonLake Immunotherapeutics (NASDAQ: MLTX) operates in the Biotechnology Research industry.

What technology does MoonLake Immunotherapeutics (NASDAQ: MLTX) use?

Minus sign iconPlus sign icon
MoonLake Immunotherapeutics (NASDAQ: MLTX)'s tech stack includes SAPApple iCloud Mail.NETAkamai Web Application ProtectorAdobe Tag ManagerAdobe Creative SuiteX-Content-Type-OptionsGoDaddy.

What is MoonLake Immunotherapeutics (NASDAQ: MLTX)'s email format?

Minus sign iconPlus sign icon
MoonLake Immunotherapeutics (NASDAQ: MLTX)'s email format typically follows the pattern of F.Last@moonlaketx.com. Find more MoonLake Immunotherapeutics (NASDAQ: MLTX) email formats with LeadIQ.

How much funding has MoonLake Immunotherapeutics (NASDAQ: MLTX) raised to date?

Minus sign iconPlus sign icon
As of February 2026, MoonLake Immunotherapeutics (NASDAQ: MLTX) has raised $75M in funding. The last funding round occurred on Apr 03, 2025 for $75M.

When was MoonLake Immunotherapeutics (NASDAQ: MLTX) founded?

Minus sign iconPlus sign icon
MoonLake Immunotherapeutics (NASDAQ: MLTX) was founded in 2021.

MoonLake Immunotherapeutics (NASDAQ: MLTX)

Biotechnology ResearchZug, Switzerland51-200 Employees

MoonLake Immunotherapeutics AG is a clinical-stage biopharmaceutical company leveraging revolutionary Nanobody® technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.

Section iconCompany Overview

Headquarters
29 Dorfstrasse Zug, Zug 6300 Switzerland
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2021
Employees
51-200

Section iconFunding & Financials

  • $75M

    MoonLake Immunotherapeutics (NASDAQ: MLTX) has raised a total of $75M of funding over 4 rounds. Their latest funding round was raised on Apr 03, 2025 in the amount of $75M.

  • $1M$10M

    MoonLake Immunotherapeutics (NASDAQ: MLTX)'s revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $75M

    MoonLake Immunotherapeutics (NASDAQ: MLTX) has raised a total of $75M of funding over 4 rounds. Their latest funding round was raised on Apr 03, 2025 in the amount of $75M.

  • $1M$10M

    MoonLake Immunotherapeutics (NASDAQ: MLTX)'s revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.